

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A method for inhibiting a condition characterized by monocytic infiltrates, wherein said method comprises administering to a patient a therapeutically effective amount of an MCP-1 receptor antagonist in a suitable pharmaceutical carrier, wherein said MCP-1 receptor antagonist is an antibody ~~or binding fragment thereof~~ which binds to an MCP-1 receptor polypeptide comprising SEQ ID NO: 2 or SEQ ID NO: 4.

Claim 2-3 (canceled).

Claim 4 (currently amended): The method of claim 3 1, wherein said pharmaceutical composition contains about 10 µg/ml to about 1 mg/ml of the antagonist.

Claim 5-6 (canceled).

Claim 7 (previously amended): The method of claim 1, wherein said antibody is a monoclonal antibody.

Claim 8 (canceled).

Claim 9 (original): The method of claim 1, wherein said condition is atherosclerosis.

Claim 10 (currently amended): A method for inhibiting MCP-1 receptor ~~polypeptide~~ activation, wherein said method comprises administering to a patient a therapeutically effective amount of an MCP-1 receptor antagonist in a suitable pharmaceutical carrier, wherein said MCP-1 receptor antagonist is an antibody ~~or binding fragment thereof~~ which binds to said MCP-1 receptor ~~polypeptide~~ SEQ ID NO: 2 or SEQ ID NO: 4.

Claim 11-12 (canceled).

Claim 13 (currently amended): The method of claim ~~12~~ 10, wherein said pharmaceutical composition contains about 10 µg/ml to about 1 mg/ml of the antagonist.

Claim 14-15 (canceled).

Claim 16 (previously amended): The method of claim 10, wherein said antibody is a monoclonal antibody.

Claim 17 (canceled).

Claim 18 (new): The method of claims 1 or 10, wherein the antibody is a Fab antibody fragment.